Form 4: Apellis Pharmaceuticals Executive Sells 9,913 Shares of Common Stock
SEC Form 4 Filing
Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 9,913 shares of common stock on March 18, 2024, at a price of $56.9 per share.
Summary
- On March 18, 2024, Mark Jeffrey DeLong, the Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 9,913 shares of the company's common stock.
- The sale was executed at a price of $56.9 per share.
- Following the transaction, DeLong directly owns 54,693 shares of Apellis Pharmaceuticals' common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating an executive's stock sale. It's a neutral event, not inherently positive or negative, thus a score of 5.
Industry Context
Executive stock sales are a common occurrence and are publicly disclosed to maintain transparency in the market. The sale could be for personal financial planning reasons and doesn't necessarily reflect a negative outlook on the company.
Stakeholder Impact
- The sale of shares by a company executive may cause short-term fluctuations in the stock price, potentially impacting shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/18/2024 | Date of transaction: Mark DeLong sold 9,913 shares of Apellis Pharmaceuticals common stock. |
| 03/19/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.